Biosimilars Create Class-wide Competition, German Experience Finds
Executive Summary
Follow-on biologics may be able to achieve broader market penetration if they are not deemed to be interchangeable or substitutable for a single reference product, according to Novartis
You may also be interested in...
New Brand, Same MS Drug: Novartis Launches Extavia In Europe
Novartis lays foundation for potential MS platform with European launch of its own branded version of Bayer-Schering’s Betaferon (interferon beta-1b).
Biosimilar Competition Debate: Must Products Be Interchangable To Generate Savings?
FTC hears arguments on whether the number of competitors, or their pharmacy-level substitutability, drives prices lower.
Biosimilars Should Face Patent Challenges Only After Approval, Novartis Says
Linking patent disputes to regulatory approval of follow-on biologics would provide no competitive benefit for patients and could discourage innovation, contends Robert Pelzer, head of Novartis' North American operations